Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seragen

Executive Summary

Hopkinton, Mass. biotech begins Phase I/II trial of interleukin-2 receptor-targeted fusion toxin DAB389IL-2 for the early treatment of HIV infection. The trial, being conducted at Boston City, Beth Israel and Johns Hopkins hospitals, will include approximately 15 to 20 patients with no opportunistic infections who are not currently on anti-retroviral therapy. DAB389IL-2, Seragen's follow-on to its older fusion toxin DAB486IL-2, is currently in Phase I/II trials for severe rheumatoid arthritis and chemotherapy-resistant, IL-2 receptor-expressing lymphomas. The firm filed an IND for the HIV trial in December of last year.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022634

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel